Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,052.50DKK
10:59am EDT
Change (% chg)

kr.0.50 (+0.05%)
Prev Close
kr.1,052.00
Open
kr.1,053.00
Day's High
kr.1,075.50
Day's Low
kr.1,051.00
Volume
95,544
Avg. Vol
222,391
52-wk High
kr.1,474.00
52-wk Low
kr.880.80

Select another date:

Mon, May 28 2018

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.

Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN, May 28 Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.

BRIEF-Genmab: Q1 Net Sales Of Darzalex At $432 Mln

* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

BRIEF-Genmab ‍2017 Operating Profit Beats Expectations

* ‍PROJECTED REVENUE FOR 2018 CONSISTS PRIMARILY OF DARZALEX ROYALTIES OF APPROXIMATELY DKK 1,750 MLN THAT ARE BASED ON AN ESTIMATED USD 2.0 - 2.3 BLN OF DARZALEX NET SALES IN 2018​

Select another date: